References

gnck

Колопроктология

Koloproktologia

2073-75562686-7303

Russian Association of Coloproctology

10.33878/2073-7556-2019-18-4-7-36

gnck-1541

Research Article

КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ

CLINICAL GUIDELINES

ПРОЕКТ КЛИНИЧЕСКИХ РЕКОМЕНДАЦИЙ ПО ДИАГНОСТИКЕ И ЛЕЧЕНИЮ ЯЗВЕННОГО КОЛИТА

PROJECT: CLINICAL GUIDELINES FOR THE DIAGNOSTICS AND TREATMENT OF ULCERATIVE COLITIS

Ивашкин

В. Т.

Ivashkin

V. T.

Шелыгин

Ю. А.

Shelygin

Yu. A.

Белоусова

Е. А.

Belousova

E. A.

Абдулганиева

Д. И.

Abdulganieva

D. I.

Алексеева

О. А.

Alekseeva

O. A.

Ачкасов

С. И.

Achkasov

S. I.

Валуйских

Е. Ю.

Valuiskikh

E. Yu.

Варданян

А. В.

Vardanyan

A. V.

Веселов

А. В.

Veselov

A. V.

Веселов

В. В.

Veselov

V. V.

Головенко

О. В.

Golovenko

O. V.

Губонина

И. В.

Gubonina

I. V.

Жигалова

Т. Н.

Zhigalova

T. N.

Кашников

В. Н.

Kashnikov

V. N.

Князев

О. В.

Knyazev

O. V.

Макарчук

П. А.

Makarchuk

P. A.

Москалев

А. И.

Moskaliev

A. I.

Нанаева

Б. А.

Nanaeva

B. A.

Низов

А. А.

Nizov

A. A.

Никитина

Н. В.

Nikitina

N. V.

Николаева

Н. Н.

Nikolaeva

N. N.

Павленко

В. В.

Pavlenko

V. V.

Полуэктова

Е. А.

Poluektova

E. A.

Светлова

И. О.

Svetlova

I. O.

Тарасова

Л. В.

Tarasova

L. V.

Ткачев

А. В.

Tkachev

A. V.

Фролов

С. А.

Frolov

S. A.

Хлынова

О. В.

Khlynova

O. V.

Чашкова

Е. Ю.

Chashkova

E. Yu.

Шапина

М. В.

Shapina

M. V.

Шептулин

А. А.

Sheptulin

A. A.

Шифрин

О. С.

Shifrin

O. S.

Щукина

О. Б.

Shchukina

O. B.

2019

04122019

184736

Copyright © Ивашкин В.Т., Шелыгин Ю.А., Белоусова Е.А., Абдулганиева Д.И., Алексеева О.А., Ачкасов С.И., Валуйских Е.Ю., Варданян А.В., Веселов А.В., Веселов В.В., Головенко О.В., Губонина И.В., Жигалова Т.Н., Кашников В.Н., Князев О.В., Макарчук П.А., Москалев А.И., Нанаева Б.А., Низов А.А., Никитина Н.В., Николаева Н.Н., Павленко В.В., Полуэктова Е.А., Светлова И.О., Тарасова Л.В., Ткачев А.В., Фролов С.А., Хлынова О.В., Чашкова Е.Ю., Шапина М.В., Шептулин А.А., Шифрин О.С., Щукина О.Б., 2019

2019

Ивашкин В.Т., Шелыгин Ю.А., Белоусова Е.А., Абдулганиева Д.И., Алексеева О.А., Ачкасов С.И., Валуйских Е.Ю., Варданян А.В., Веселов А.В., Веселов В.В., Головенко О.В., Губонина И.В., Жигалова Т.Н., Кашников В.Н., Князев О.В., Макарчук П.А., Москалев А.И., Нанаева Б.А., Низов А.А., Никитина Н.В., Николаева Н.Н., Павленко В.В., Полуэктова Е.А., Светлова И.О., Тарасова Л.В., Ткачев А.В., Фролов С.А., Хлынова О.В., Чашкова Е.Ю., Шапина М.В., Шептулин А.А., Шифрин О.С., Щукина О.Б.

Ivashkin V.T., Shelygin Y.A., Belousova E.A., Abdulganieva D.I., Alekseeva O.A., Achkasov S.I., Valuiskikh E.Y., Vardanyan A.V., Veselov A.V., Veselov V.V., Golovenko O.V., Gubonina I.V., Zhigalova T.N., Kashnikov V.N., Knyazev O.V., Makarchuk P.A., Moskaliev A.I., Nanaeva B.A., Nizov A.A., Nikitina N.V., Nikolaeva N.N., Pavlenko V.V., Poluektova E.A., Svetlova I.O., Tarasova L.V., Tkachev A.V., Frolov S.A., Khlynova O.V., Chashkova E.Y., Shapina M.V., Sheptulin A.A., Shifrin O.S., Shchukina O.B.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.ruproctology.com/jour/article/view/1541

References1

Travis SP, Dinesen L. Remission in trials of ulcerative colitis: what does it mean? Pract Gastroenterol. 2010;30:17-20.

D'Haens G, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763-86.

D'Haens G, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcer-ative colitis. Gastroenterology. 2007;132:763-86.

Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785-94.

Белоусова Е.А., Абдулганиева Д.И., Алексеева О.П., Алексеенко С.А. и соавт. Социально-демографическая характеристика, особенности течения и варианты лечения воспалительных заболеваний кишечника в России. Результаты двух многоцентровых исследований. Альманах клинической медицины. 2018;46(5):445-463. https://doi.org/10.18786/2072-0505-2018-46-5-445-463.

Belousova E.A., Abdulganieva D.I., Alexeeva O.P., Alexeenko S.A. et al. Social and demographic characteristics, features of disease course and treatment options of inflammatory bowel disease in Russia: results of two multicenter studies. Almanac of Clinical Medicine. 2018;46(5):445-463. https://doi.org/10.18786/2072-0505-2018-46-5-445-463 (In Russ.)

Katsanos KH, Vermeire S, Christodoulou DK, Riis L et al. Dysplasia and cancer in inflammatory bowel disease 10 years after diagnosis: results of a population-based European collaborative follow-up study. Digestion. 2007;75: 113-21.

Katsanos KH, Vermeire S, Christodoulou DK, Riis L, et al. Dysplasia and cancer in inflammatory bowel disease 10 years after diagnosis: results of a population-based European collaborative follow-up study. Digestion. 2007;75: 113-21.

Silverberg MS, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(Suppl A):5-36.

Truelove SC et al. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2:1041-8.

Seah D, De Cruz P. Review article: the practical management of acute severe ulcerative colitis. Aliment Pharmacol Ther. 2016 Feb;43(4):482-513.

Hindryckx P, Jairath V, D'Haens G. Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat Rev Gastroenterol Hepatol. 2016 Sep 1.

Chen JH, Andrews JM, Kariyawasam V, Moran N. IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group. Review article: acute severe ulcerative colitis – evidence-based consensus statements. Aliment Pharmacol Ther. 2016 Jul;44(2):127-44.

Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-9.

Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-amino-salicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-9.

Григорьева Г.А., Мешалкина Н.Ю. О проблеме системных проявлений воспалительных заболеваний кишечника. Фарматека. 2011; № 15, с. 44-49.

Grigor’eva GA, Meshalkina NYu. On The Problem Of Systemic Manifestations Of Inflammatory Bowel Diseases. Farmateka. 2011; 5: 44-49. (In Russ.)

Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology. 2004;126:1518-32.

Perler B, Ungaro R, Baird G, Malette M. et al. Presenting symptoms in inflammatory bowel disease: descriptive analysis of a community-based inceptive cohort. BMC Gastroenterol. 2019; 19:47.

Perler B, Ungaro R, Baird G, Malette M. et al. Presenting symp-toms in inflammatory bowel disease: descriptive analysis of a community-based inceptive cohort. BMC Gastroenterol. 2019; 19:47.

Fine KD, Schiller LR. AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology. 1999;116:1464-86.

Forrest K, Symmons D, Foster P. Systematic review: is ingestion of paracetamol or non-steroidal anti-inflammatory drugs associated with exacerbations of inflammatory bowel disease? Aliment Pharmacol Ther. 2004;20:1035-43.

Forrest K, Symmons D, Foster P. Systematic review: is ingestion of paracetamol or non-steroidal anti-inflammatory drugs associ-ated with exacerbations of inflammatory bowel disease? Aliment Pharmacol Ther. 2004;20:1035-43.

Mahid SS, Minor KS, Soto RE, et al. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc. 2006;81:1462-71.

Vermeire S. Review article: genetic susceptibility and application of genetic testing in clinical management of inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24:2-10.

Vermeire S. Review article: genetic susceptibility and applica-tion of genetic testing in clinical management of inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24:2-10.

Carter MJ, Lobo AJ, Travis SP; IBD Section, British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53:V1-16.

Dignass A, et al. Second EUROPEAN evidence-based Consensus on the diagnosis and management of ulcerative colitis: Current management, Journal of Crohn's and Colitis. 2012.

Travis SP, Jewell DP. Ulcerative colitis: clinical presentation and diagnosis. In: Satsangi J, Sutherland LR, editors. Inflammatory Bowel Diseases. London: Churchill Livingstone. 2003: 169-81.

Lucendo AJ, Arias Á, Roncero Ó, Hervías D, et al. Anemia at the time of diagnosis of inflammatory bowel disease: Prevalence and associated factors in adolescent and adult patients. Sao Paulo Med J. 2014;132(3):140-6.

Irwin JR, Ferguson E, Simms LA, Hanigan K, et al. Detectable Laboratory Abnormality Is Present up to 12 Months Prior to Diagnosis in Patients with Crohn's Disease. Dig Dis Sci. 2019 Feb;64(2):503-517.

Cherfane CE, Gessel L, Cirillo D, Zimmerman MB, Polyak S. Monocytosis and a Low Lymphocyte to Monocyte Ratio Are Effective Biomarkers of Ulcerative Colitis Disease Activity. Inflamm Bowel Dis. 2015 Aug;21(8):1769-75.

Feng JR, Qiu X, Wang F, Chen PF, et al. Diagnostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Crohn's Disease. Gastroenterol Res Pract. 2017;2017:3526460. doi: 10.1155/2017/3526460.

Yoon JY, Park SJ, Hong SP, Kim TI, et al. Correlations of C-reactive protein levels and erythrocyte sedimentation rates with endoscopic activity indices in patients with ulcerative colitis. Dig Dis Sci. 2014 Apr;59(4):829-37.

Yamamoto-Furusho JK, Sánchez-Osorio M, Uribe M. Prevalence and factors associated with the presence of abnormal function liver tests in patients with ulcerative colitis. Ann Hepatol. 2010 Oct-Dec;9(4):397-401

Archampong EQ, Harris J, Clark CG. The absorption and secretion of water and electrolytes across the healthy and the diseased human colonic mucosa measured in vitro. Gut. 1972 Nov;13(11):880-6.

Maharshak N, Arbel Y, Gal-Oz A, Rogowski O, et al. Comparative analysis of Bayer wide-range C-reactive protein (wr-CRP) and the Dade-Behring high sensitivity C-reactive protein (hs-CRP) in patients with inflammatory bowel disease. J Dig Dis. 2008 Aug;9(3):140-3.

Weber P, Husemann S, Vielhaber H, Zimmer KP, Nowak-Göttl U. Coagulation and fibrinolysis in children, adolescents, and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1999 Apr;28(4):418-22.

Issa M, Vikayapal A, Gracham MB et al. Impact of Clostridium difficile in inflammatory bowel disease patients. Clin Gastroenterol Hepatol. 2007; 5: 345-351.

Rodeman JF, Dubberke ER, Reske KA et al. Incidence of Clostridium difficile in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007; 5: 339-344.

Issa M, Ananthakrishnan AN, Binion DG. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14:1432-42.

Issa M, Ananthakrishnan AN, Binion DG. Clostridium dif-ficile and inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14:1432-42.

Nguyen GC, Kaplan GG, Harris ML et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008; 103: 1443-50.

Mindenmark M, Larsson A. Rulling out IBD estimation of the possible economic effects of pre-endoscopic screening with F-calprotectin. Clin Biochem. 2012; 45: 552-5.

Costa F, Mumolo MG, Bellini M, Romano MR et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis. 2003;35:642-7.

Costa F, Mumolo MG, Bellini M, Romano MR, et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis. 2003;35:642-7.

Kim JJ, Simpson N, Klipfel N, Debose R, et al. Cytomegalovirus infection in patients with active inflammatory bowel disease. Dig Dis Sci. 2010 Apr;55(4):1059-65. doi: 10.1007/s10620-010-1126-4.

Lin WC, Chang CW, Chen MJ, Hsu TC, Wang HY. Effectiveness of sigmoidoscopy for assessing ulcerative colitis disease activity and therapeutic response. Medicine (Baltimore). 2019 May;98(21):e15748. doi: 10.1097/MD.0000000000015748.

Lin WC, Chang CW, Chen MJ, Hsu TC, Wang HY. Effectiveness of sigmoidoscopy for assessing ulcerative colitis disease activ-ity and therapeutic response. Medicine (Baltimore). 2019 May;98(21):e15748. doi: 10.1097/MD.0000000000015748.

Bansal J, Jenaw RK, Rao J, et al. Effectiveness of plain radiography in diagnosing hollow viscus perforation: study of 1,723 patients of perforation peritonitis. Emerg Radiol. 2012 Apr;19(2):115-9. doi: 10.1007/s10140-011-1007-y.

Colombel JF, Ordás I, Ullman T, Rutgeerts Pet al. Agreement Between Rectosigmoidoscopy and Colonoscopy Analyses of Disease Activity and Healing in Patients With Ulcerative Colitis. Agreement Between Rectosigmoidoscopy and Colonoscopy Analyses of Disease Activity and Healing in Patients With Ulcerative Colitis. Gastroenterology. 2016 Feb; 150(2):389-95.e3. doi: 10.1053/j.gastro.2015.10.016.

Annese V, Daperno M, Rutter M.D., et al. European evidence based consensus for endoscopy in inflammatory bowel disease. Journal of Crohn’s and Colitis. 2013; 7(12): 982-1018.

Tanaka M, Saito H, Fukuda S, Sasaki Y, et al. Simple mucosal biopsy criteria differentiating among Crohn disease, ulcerative colitis, and other forms of colitis: measurement of validity. Scand J Gastroenterol. 2000 Mar;35(3):281-6.

Parente F, Greco S, Molteni M, et al. Role of early ultrasound in detecting inflammatory intestinal disorders and identifying their anatomical location within the bowel. Alimentary Pharmacology and Therapeutics. 2003;18:1009-1016.

Socaciu M, Ciobanu L, Diaconu B, Hagiu C, et al. Non-Invasive Assessment of Inflammation and Treatment Response in Patients with Crohn's Disease and Ulcerative Colitis using Contrast-Enhanced Ultrasonography Quantification. J Gastrointestin Liver Dis. 2015 Dec;24(4):457-65. doi: 10.15403/jgld.2014.1121.244.chr.

Pouillon L, Laurent V, Pouillon M, Bossuyt P et al. Diffusion-weighted MRI in inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2018 Jun;3(6):433-443. doi: 10.1016/S2468-1253(18)30054-2.

Kılıçkesmez O, Soylu A, Yaşar N, Demirbaş T, Dolapçıoğlu C, et al. Is quantitative diffusion-weighted MRI a reliable method in the assessment of the inflammatory activity in ulcerative colitis? Diagn Interv Radiol. 2010 Dec;16(4):293-8. doi: 10.4261/1305-3825.DIR.2989-09.1.

Jia Y, Li C, Yang X, Dong Z, et al. CT Enterography score: a potential predictor for severity assessment of active ulcerative colitis. BMC Gastroenterol. 2018 Nov 9;18(1):173. doi: 10.1186/s12876-018-0890-z.

Gashin L, Villafuerte-Galvez J, Leffler DA, et al. Utility of CT in the emergency department in patients with ulcerative colitis. Inflamm Bowel Dis. 2015 Apr;21(4):793-800. doi: 10.1097/MIB.0000000000000321.

Gashin L, Villafuerte-Galvez J, Leffler DA, et al. Utility of CT in the emergency department in patients with ulcerative coli-tis. Inflamm Bowel Dis. 2015 Apr;21(4):793-800. doi: 10.1097/MIB.0000000000000321.

Милько В.И., Минцер О.П., Топчий Т.В., Корсуновский А.А. Клиническая оценка данных ирригоскопии при неспецифическом язвенном колите. Вест., рентгенологии и радиологии. 1983; № 5, с. 46-50.

Mil'ko V.I., Mincher O.P., Topchiy T.V., Korsunovskiy A.A. Clinical assessment of irrigoscopy data in ulcerative colitis. Vestnik rent-genologii i radiologii. 1983; 5:46-50. (In Russ.)

Корнеева О.И., Ивашкин В.Т. Антибиотикоассоциированный колит: патоморфология, клиника, лечение. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2007; т. 17. № 3, с. 65-71

Korneeva O.I., Ivashkin V.T. Cl.Difficile colitis: pathomorfol-ogy, symptoms and treatment. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2007; 17(3):65-71 (In Russ.).

Ивашкин В.Т., Шептулин А.А., Шифрин О. С., Галимова С.Ф., и соавт. Микроскопический колит: клинические формы, диагностика, лечение. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2006; т. 16, № 6, с. 56-60.

Ivashkin V.T., Sheptulin A.A., Shifrin O.S., Galimova S.F. et al. Microscopic colitis: clinical forms, diagnosis and treatment. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2006; 16(6):56-60. (In Russ.).

Белоусова Е.А., Никитина Н.В., Цодикова О.М. Лечение язвенного колита легкого и среднетяжелого течения. Фарматека. 2013; № 2, с. 42-46.

Belousova E.A., Nikitina N.V., Tsodikova O.M. Treatment Of Mild To Moderate Ulcerative Colitis. Farmateka. 2013; 2: 42-46. (In Russ.).

Халиф И.Л. Принципы лечения язвенного колита (Рекомендации российской группы по изучению воспалительных заболеваний кишечника). Колопроктология, 2006; №2; с. 31-33.

Khalif I.L. Treatment strategies in ulcerative colitis (Russian inflammatory bowel disease group guidelines). Koloproktologia. 2006;2:31-33 (In Russ.)

Халиф И.Л. Лечебная тактика при язвенном колите. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2006; т. 16, № 3, с. 58-62.

Khalif I.L. Treatment strategies in ulcerative colitis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2006; 16(3):58-62. (In Russ.).

Marshall JK, Thabane M, Steinhart AH, Newman JR et al. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010 [CD004115-CD004115].

Marshall JK, Thabane M, Steinhart AH, Newman JR, et al. Rectal 5-aminosalicylic acid for induction of remission in ulcerative coli-tis. Cochrane Database Syst Rev. 2010 [CD004115-CD004115].

Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut. 1997;40: 775-81.

Marshall JK, Irvine EJ. Rectal corticosteroids versus alterna-tive treatments in ulcerative colitis: a meta-analysis. Gut. 1997;40: 775-81.

Lamet M. A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg twice daily in patients with active mild-to-moderate ulcerative proctitis. Dig Dis Sci. 2011;56:513-22.

Safdi M, DeMicco M, Sninsky C, Banks P, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997;92:1867-71.

Safdi M, DeMicco M, Sninsky C, Banks P, et al. A double-blind comparison of oral versus rectal mesalamine versus combina-tion therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997;92:1867-71.

Gecse KB1, Lakatos PL. Ulcerative proctitis: an update on the pharmacotherapy and management. Expert Opin Pharmacother. 2014;15(11):1565-73.

Ahmed I, Kassem W, Salam Y, Furnari M, Mehta T. Outcome of Cytomegalovirus Colitis in Inflammatory Bowel Disease with Different Regimes of Ganciclovir. Middle East J DigDis. 2018 Oct;10(4):220-229. doi: 10.15171/mejdd.2018.114.

Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006:CD000543.

Regueiro M, Loftus Jr EV, Steinhart AH, Cohen RD. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis. 2006;12:979-94.

Regueiro M, Loftus Jr EV, Steinhart AH, Cohen RD. Medical management of left-sided ulcerative colitis and ulcerative proc-titis: critical evaluation of therapeutic trials. Inflamm Bowel Dis. 2006;12:979-94.

Ford AC, Achkar J-P, Khan KJ, Kane SV, Talley NJ et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:601-16.

Ford AC, Achkar J-P, Khan KJ, Kane SV, Talley NJ, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:601-16.

Ford AC, Khan KJ, Achkar JP, et al. Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in Ulcerative Colitis: systematic review and meta-analysis. The American journal of gastroenterology. 2012;107:167-76;

Kane SV, Bjorkman DJ. The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review. Rev Gastroenterol Disord. 2003;3:210-8.

Kane SV, Bjorkman DJ. The efficacy of oral 5-ASAs in the reatment of active ulcerative colitis: a systematic review. Rev Gastroenterol Disord. 2003;3:210-8.

Danielsson A, Löfberg R, Persson T, Salde L, et al. A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis. Scand J Gastroenterol. 1992;27(1):9-12.

Nguyen NH, Fumery M, Dulai PS, Prokop LJ,et al. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses. Lancet Gastroenterol Hepatol. 2018 Nov;3(11):742-753. doi: 10.1016/S2468-1253(18)30231-0.

Nguyen NH, Fumery M, Dulai PS, Prokop LJ,et al. Comparative efficacy and tolerability of pharmacological agents for manage-ment of mild to moderate ulcerative colitis: a systematic review and network meta-analyses. Lancet Gastroenterol Hepatol. 2018 Nov;3(11):742-753. doi: 10.1016/S2468-1253(18)30231-0.

D'Haens G. Systematic review: second-generation vs. conventional corticosteroids for induction of remission in ulcerative colitis. Aliment Pharmacol Ther. 2016;44:1018-1029.

D'Haens G. Systematic review: second-generation vs. con-ventional corticosteroids for induction of remission in ulcerative colitis. Aliment Pharmacol Ther. 2016;44:1018-1029.

Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006:CD000543.

Feagan BG, MacDonald JK. Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and metaanalysis. Inflammatory bowel diseases. 2012;18:1785-94.

Feagan BG, MacDonald JK. Once daily oral mesalamine com-pared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysis. Inflammatory bowel diseases. 2012;18:1785-94.

Lichtenstein GR. Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis. Dig Dis Sci. 2016 Feb;61(2):358-70.

Sherlock ME, MacDonald JK, Griffiths AM, Steinhart AH, Seow CH. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2015 Oct 26;(10):CD007698.

Danese S, Siegel CA, Peyrin-Biroulet L. Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther. 2014 May;39(10):1095-103.

Danese S, Siegel CA, Peyrin-Biroulet L. Review article: inte-grating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther. 2014 May;39(10):1095-103.

Timmer A, Patton PH, Chande N, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016:Cd000478.

Timmer A, Patton PH, Chande N, et al. Azathioprine and 6-mer-captopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016:Cd000478.

Gisbert JP, Linares PM, McNicholl AG, Mate J, Gomollon F. Metaanalysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther. 2009;30:126-37.

Gisbert JP, Linares PM, McNicholl AG, Mate J, Gomollon F. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcer-ative colitis. Aliment Pharmacol Ther. 2009;30:126-37.

Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine. 2005;353:2462-2476.

Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257-65 e1-3.

Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with mod-erate-to-severe ulcerative colitis. Gastroenterology. 2014;146:85-95; quiz e14-5.

Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golim-umab induces clinical response and remission in patients with mod-erate-to-severe ulcerative colitis. Gastroenterology. 2014;146:85-95; quiz e14-5.

Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. The New England journal of medicine. 2013;369:699-710.

Sandborn W SB, D'Haens GR, et al. Efficacy and safety of oral tofacitinib as induction therapy in patients with moderate to severe ulcerative colitis: results from two phase 3 randomized controlled trials. Gastroenterology. 2016:S157.

Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146:392-400.e3.

Panaccione R, Ghosh S, Middleton S, et al. Infliximab, azathioprine or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis. The UC SUCCESS trial. J Crohns Colitis. 2011;5:13.

Panaccione R, Ghosh S, Middleton S, et al. Infliximab, aza-thioprine or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis. The UC SUCCESS trial. J Crohns Colitis. 2011;5:13.

Yarur AJ, Rubin DT. Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2015 Jul;21(7):1709-18.

Steenholdt C, Bendtzen K, Brynskov J, Ainsworth MA. Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies. Inflamm Bowel Dis. 2016 Aug;22(8):1999-2015.

Sandborn WJ, C Su, Sands BE, et al. OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723-36.

Reinisch W, Sandborn WJ, Rutgeerts P, et al. Long-term inflix-imab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis. 2012;18:201-11.

Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257-65 e1-3.

Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moder-ate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257-65 e1-3.

Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:96-109.e1.

Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. The New England journal of medicine. 2013;369:699-710.

Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induc-tion and maintenance therapy for ulcerative colitis. The New England journal of medicine. 2013;369:699-710.

Danese S, D'Amico F, Bonovas S, Peyrin-Biroulet L. Positioning Tofacitinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis. Inflamm Bowel Dis. 2018 Apr 25.

Shmidt E, Kochhar G, Hartke J, et al. Predictors and Management of Loss of Response to Vedolizumab in Inflammatory. Bowel Disease Inflamm Bowel Dis. 2018;18 [Epub ahead of print].

Sands BE et al. DOP026 Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with ulcerative colitis follow-ing loss of response on tofacitinib 5 mg BID maintenance therapy: results from OCTAVE open. Journal of Crohn's and Colitis. vol. 12, Issue supplement_1, 16 January 2018, Pages S049, https://doi.org/10.1093/ecco-jcc/jjx180.063

Халиф И.Л., Нанаева Б.А., Головенко А.О., Головенко О.В. Отдаленные результаты консервативного лечения больных с тяжелым обострением язвенного колита. Терапевтический архив. 2015;87(2):34-38. https://doi.org/10.17116/terarkh201587234-38

Khalif I.L., Nanaeva B.A., Golovenko A.O., Golovenko O.V. Long-term results of conservative treatment of patients with severe exacerbation of ulcerative colitis. Terapevticheskii arhiv. 2015;87(2):34-38. https://doi.org/10.17116/terarkh201587234-38

Turner D, Walsh CM, Steinhart AH, et al. Response to corti-costeroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5:103-110.

Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015;9:211-22.

Dignass AU, Gasche C, Bettenworth D, et al. European consen-sus on the diagnosis and management of iron deficiency and anae-mia in inflammatory bowel diseases. J Crohns Colitis. 2015;9:211-22.

Gonzalez-Huix F, Fernandez-Banares F, Esteve-Comas M, et al. Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis. Am J Gastroenterol. 1993;88:227-32.

Gonzalez-Huix F, Fernandez-Banares F, Esteve-Comas M, et al. Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis. Am J Gastroenterol. 1993;88:227-32

Parlak E, Dağli U, Ulker A, et al. Comparison of 5-amino salicylic acid plus glucocorticosteroid with metronidazole and ciprofloxacin in patients with active ulcerative colitis. J Clin Gastroenterol. 200;33(1):85-6xxxiv.

Parlak E, Dağli U, Ulker A, et al. Comparison of 5-amino salicylic acid plus glucocorticosteroid with metronidazole and ciprofloxa-cin in patients with active ulcerative colitis. J Clin Gastroenterol. 200;33(1):85-6xxxiv.

Khan KJ, Ullman TA, Ford AC, Abreu MT, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and metaanalysis. Am J Gastroenterol. 2011;106:661-73.

Khan KJ, Ullman TA, Ford AC, Abreu MT, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106:661-73.

100

Ohkusa T, Kato K, Terao S, Chiba T, et al. Newly developed antibiotic combination therapy for ulcerativecolitis: a doubleblind placebo-controlled multicenter trial. Am J Gastroenterol. 2010;105:1820-9.

Ohkusa T, Kato K, Terao S, Chiba T, et al. Newly developed antibiotic combination therapy for ulcerativecolitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol. 2010;105:1820-9.

101

Järnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a random-ized, placebo-controlled study. Gastroenterology. 2005;128:1805-11.

102

Lees CW, Heys D, Ho GT, Noble CL et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2007;26:411-9.

103

Van Assche G, D'Haens G, Noman M, Vermeire S, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. 2003;125:1025-31.

104

Sjoberg M, Walch A, Meshkat M, Gustavsson A, et al. Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational study. Inflamm Bowel Dis. 2012; 18(2), p. 212-8.

105

Головенко А.О., Халиф И.Л., Головенко О.В., Веселов В.В. Предикторы эффективности инфликсимаба у больных с тяжелой атакой язвенного колита. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2013;5(23):65-73.

Golevenko A.O., Khaif I.L., Golovenko O.V., Veselov V.V. Infliximab efficiency predictors in patients with severe ulcerous colitis attack. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2013; no.5, v. 23, pp. 65-73. (In Russ.)

106

Sokol H, Seksik P, Carrat F, Nion-Larmurier I, et al. Usefulness of co-treatment with immunomodulators in patients with inflam-matory bowel disease treated with scheduled infliximab mainte-nance therapy. Gut. 2010;59:1363-8.

107

Reinisch W, Sandborn WJ, Rutgeerts P, Feagan BG, et al. Lonterm infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis. 2012;18:201-11.

Reinisch W, Sandborn WJ, Rutgeerts P, Feagan BG, et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis. 2012;18:201-11.

108

Chebli LA, LDdM Chaves, Pimentel FF, Guerra DM, et al. Azathioprine maintains long-term steroid-free remission through 3 years in patients with steroid-dependent ulcerative colitis. Inflamm Bowel Dis. 2010;16:613-9.

109

Ardizzone S, Maconi G, Russo A, Imbesi V, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treat-ment of steroid dependent ulcerative colitis. Gut. 2006;55:47-53.

Ardizzone S, Maconi G, Russo A, Imbesi V, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treat-ment of steroid dependent ulcerative colitis. Gut. 2006;55:47-53

110

Randall JSB, Warren BF, Travis SP, Mortensen NJ, et al. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. Br J Surg. 2010;97: 404-9.

111

Lennard-Jones JE, Ritchie JK, Hilder W, Spicer CC. Assessment of severity in colitis: a preliminary study. Gut. 1975;16:579-84.

112

Travis SP, Farrant JM, Ricketts C, Nolan DJ, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38:905-10.

113

Lindgren SC, Flood LM, Kilander AF, Lofberg R et al. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol. 1998;10:831-5.

114

Benazzato L, D'Inca R, Grigoletto F, Perissinotto E, et al. Prognosis of severe attacks in ulcerative colitis: effect of intensive medical treatment. Dig Liver Dis. 2004;36:461-6.

115

Almer S, Bodemar G, Franzen L, Lindstrom E, et al. Use of air enema radiography to assess depth of ulceration during acute attacks of ulcerative colitis. Lancet. 1996;347: 1731-5.

116

Carbonnel F, Lavergne A, Lemann M, Bitoun A, et al. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci. 1994;39: 1550-7.

117

Ferrante M, Vermeire S, Katsanos KH. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis. 2007 Feb;13(2):123-8.

118

Gonzalez-Lama Y, Fernandez-Blanco I, Lopez-SanRoman A. Open-label infliximab therapy in ulcerative colitis: a multicenter survey of results and predictors of response. Hepatogastroenterology. 2008 Sep-Oct;55(86-87):1609-14.

119

Fasanmade AA, Adedokun OJ, Olson A, Strauss R, et al. Serum albumin concentration: a predictive factor of infliximab pharma-cokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther. 2010 May;48(5):297-308.

120

Oussalah A, Evesque L, Laharie D, Roblin X. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol. 2010 Dec;105(12):2617-25.

Oussalah A, Evesque L, Laharie D, Roblin X. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitaliza-tion. Am J Gastroenterol. 2010 Dec;105(12):2617-25.

121

Cacheux W, Seksik P, Lemann M, Marteau P, et al. Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. Am J Gastroenterol. 2008; 103: 637-42.

122

Monterubbianesi R, Aratari A, Armuzzi A, Daperno M, et al. Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy. J CrohnsColitis. 2014; 8: 852-8.

123

124

Gan SI, Beck PL. A new look at toxic megacolon: an update and review of incidence, etiology, pathogenesis, and management. Am J Gastroenterol. 2003;98:2363-2371.

125

Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526-35.

126

Jess T, Loftus Jr EV, Velayos FS, Harmsen WS, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology. 2006;130:1039-46.

127

Bergeron V, Vienne A, Sokol H, Seksik P, et al. Risk factors for neoplasia in inflammatory bowel disease patients with pancolitis. Am J Gastroenterol. 2010, [advance online publication, 15 June 2010].

128

Rutter M, Saunders B, Wilkinson K, Rumbles S, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451-9.

129

Richards DM, Hughes SA, Irving MH, Scott NA. Patient quality of life after successful restorative proctocolectomy is normal. Colorectal Dis. 2001;3:223-6.

Richards DM, Hughes SA, Irving MH, Scott NA. Patient qual-ity of life after successful restorative proctocolectomy is normal. Colorectal Dis. 2001;3:223-6.

130

McLaughlin SD, Clark SK, Thomas-Gibson S, Tekkis P, et al. Guide to endoscopy of the ileo-anal pouch following restorative proctocolectomy with ileal pouch-anal anastomosis; indications, technique, and management of common findings. Inflamm Bowel Dis. 2009;15:1256-63.

131

Berndtsson I, Oresland T. Quality of life before and after proc-tocolectomy and IPAA in patients with ulcerative proctocolitis—a prospective study. Colorectal Dis. 2003;5:173-9.

132

Marcello PW, Roberts PL, Schoetz Jr DJ, Coller JA, et al. Long-term results of the ileoanal pouch procedure. Arch Surg. 1993;128:500-3 [discussion 503-4].

133

Sagar PM, Pemberton JH. Ileo-anal pouch function and dys-function. Dig Dis. 1997;15:172-88.

Sagar PM, Pemberton JH. Ileo-anal pouch function and dysfunction. Dig Dis. 1997;15:172-88.

134

Meagher AP, Farouk R, Dozois RR, Kelly KA, et al. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg. 1998;85:800-3.

135

Setti-Carraro P, Ritchie JK, Wilkinson KH, et al. The first 10 years’ experience of restorative proctocolectomy for ulcerative colitis. Gut. 1994;35:1070-1075.

136

Fazio VW, Ziv Y, Church JM, et al. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg. 1995;222:120-127.

Fazio VW, Ziv Y, Church JM, et al. Ileal pouch-anal anasto-moses complications and function in 1005 patients. Ann Surg. 1995;222:120-127.

137

Belliveau P, Trudel J, Vasilevsky CA, et al. Ileoanal anastomosis with reservoirs: complications and long-term results. Can J Surg. 1999;42: 345-352.

138

Pinto RA, Canedo J, Murad-Regadas S, Regadas SF, et al. Ileal pouch-anal anastomosis in elderly patients: is there a difference in morbidity compared with younger patients? Colorectal Dis. 2011;13:177-83.

139

Church JM. Functional outcome and quality of life in an elderly patient with an ileal pouch-anal anastomosis: a 10-year follow up. Aust N Z J Surg. 2000;70:906-7.

140

Chapman JR, Larson DW, Wolff BG, Dozois EJ, et al. Ileal pouch-anal anastomosis: does age at the timeof surgery affect outcome? Arch Surg. 2005;140:534-40.

141

Delaney CP, Dadvand B, Remzi FH, et al. Functional outcome, quality of life, and complications after ileal pouch-anal anastomosis in selected septuagenarians. Dis Colon Rectum. 2002;45:890-4.

Delaney CP, Dadvand B, Remzi FH, et al. Functional outcome, quality of life, and complications after ileal pouch-anal anastomo-sis in selected septuagenarians. Dis Colon Rectum. 2002;45:890-4.

142

Olsen KO, Joelsson M, Laurberg S, Oresland T. Fertility after ileal pouch-anal anastomosis in women with ulcerative colitis. Br J Surg. 1999;86:493-5.

143

Ording OK, Juul S, Berndtsson I, Oresland T et al. Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterology. 2002;122:15-9.

144

Gorgun E, Remzi FH, Goldberg JM, Thornton J, et al. Fertility is reduced after restorative proctocolectomy with ileal pouch anal anastomosis: a study of 300 patients. Surgery. 2004;136:795-803.

Gorgun E, Remzi FH, Goldberg JM, Thornton J, et al. Fertility is reduced after restorative proctocolectomy with ileal pouch anal anastomosis: a study of 300 patients. Surgery. 2004;136:795-803.145. Johnson P, Richard C, Ravid A, Spencer L, et al. Female infer-tility after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum. 2004;47:1119-26.

145

Johnson P, Richard C, Ravid A, Spencer L, et al. Female infer-tility after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum. 2004;47:1119-26.

Oresland T, Palmblad S, Ellstrom M, Berndtsson I, et al. Gynaecological and sexual function related to anatomical changes in the female pelvis after restorative proctocolectomy. Int J Colorectal Dis. 1994;9:77-81.

146

Burns EM, Bottle A, Aylin P, Clark SK, et al. Volume analysis of outcome following restorative proctocolectomy. Br J Surg. 2011;98:408-17.

147

Burns EM, Bottle A, Aylin P, Clark SK, et al. Volume analysis of outcome following restorative proctocolectomy. Br J Surg. 2011;98:408-17.

Alves A, Panis Y, Bouhnik Y, Maylin V, et al. Subtotal colectomy for severe acute colitis: a 20-year experience of a tertiary care center with an aggressive and early surgical policy. J Am Coll Surg. 2003;197:379-85

148

Berg DF, Bahadursingh AM, Kaminski DL, Longo WE. Acute surgical emergencies in inflammatory bowel disease. Am J Surg. 2002;184:45-51.

149

Berg DF, Bahadursingh AM, Kaminski DL, Longo WE. Acute surgical emergencies in inflammatory bowel disease. Am J Surg. 2002;184:45-51.

Hyman NH, Cataldo P, Osler T. Urgent subtotal colectomy for severe inflammatory bowel disease. Dis Colon Rectum. 2005;48: 70-3.

150

Hyman NH, Cataldo P, Osler T. Urgent subtotal colectomy for severe inflammatory bowel disease. Dis Colon Rectum. 2005;48: 70-3.

Holubar SD, Larson DW, Dozois EJ, Pattana-Arun J, et al. Minimally invasive subtotal colectomy and ileal pouch-anal anas-tomosis for fulminant ulcerative colitis: a reasonable approach? Dis Colon Rectum. 2009;52:187-92.

151

Holubar SD, Larson DW, Dozois EJ, Pattana-Arun J, et al. Minimally invasive subtotal colectomy and ileal pouch-anal anastomosis for fulminant ulcerative colitis: a reasonable approach? Dis Colon Rectum. 2009;52:187-92.

Marceau C, Alves A, Ouaissi M, Bouhnik Y, et al. Laparoscopic subtotal colectomy for acute or severe colitis complicating inflam-matory bowel disease: a case-matched study in 88 patients. Surgery. 2007;141:640.

152

Marceau C, Alves A, Ouaissi M, Bouhnik Y, et al. Laparoscopic subtotal colectomy for acute or severe colitis complicating inflammatory bowel disease: a case-matched study in 88 patients. Surgery. 2007;141:640.

Annibali R, Oresland T, Hulten L. Does the level of stapled ileo-anal anastomosis influence physiologic and functional outcome? Dis Colon Rectum. 1994;37:321-9.

153

Annibali R, Oresland T, Hulten L. Does the level of stapled ileo-anal anastomosis influence physiologic and functional outcome? Dis Colon Rectum. 1994;37:321-9.

Burns EM, Bottle A, Aylin P, Clark SK, et al. Volume analysis of outcome following restorative proctocolectomy. Br J Surg. 2011;98:408-17.

154

Burns EM, Bottle A, Aylin P, Clark SK, et al. Volume analysis of outcome following restorative proctocolectomy. Br J Surg. 2011;98:408-17.

Tekkis PP, Fazio VW, Lavery IC, Remzi FH, et al. Evaluation of the learning curve in ileal pouch-anal anastomosis surgery. Ann Surg. 2005;241:262-8.

155

Tekkis PP, Fazio VW, Lavery IC, Remzi FH, et al. Evaluation of the learning curve in ileal pouch-anal anastomosis surgery. Ann Surg. 2005;241:262-8.

Lepisto A, J. JH. Fate of the rectum after colectomy with ileo-rectal anastomosis in ulcerative colitis. Scand J Surg. 2005;94:40-2.

156

Lepisto A, J. JH. Fate of the rectum after colectomy with ileorectal anastomosis in ulcerative colitis. Scand J Surg. 2005;94:40-2.

Edwards, C.M., B. George, and B.F. Warren, Diversion colitis: new light through old windows. Histopathology. 1999. 35(1): p. 86-7.

157

Edwards, C.M., B. George, and B.F. Warren, Diversion colitis: new light through old windows. Histopathology. 1999. 35(1): p. 86-7.

Annibali R, Oresland T, Hulten L. Does the level of stapled ileo-anal anastomosis influence physiologic and functional outcome? Dis Colon Rectum. 1994;37:321-9.

158

Annibali R, Oresland T, Hulten L. Does the level of stapled ileoanal anastomosis influence physiologic and functional outcome? Dis Colon Rectum. 1994;37:321-9.

Shepherd NA, Jass JR, Duval I, Moskowitz RL, et al. Restorative proctocolectomy with ileal reservoir: pathological and histochemi-cal study of mucosal biopsy specimens. J Clin Pathol. 1987;40:601-7.

159

Shepherd NA, Jass JR, Duval I, Moskowitz RL, et al. Restorative proctocolectomy with ileal reservoir: pathological and histochemical study of mucosal biopsy specimens. J Clin Pathol. 1987;40:601-7.

Setti Carraro PG, Talbot IC, Nicholls JR. Patterns of distribu-tion of endoscopic and histological changes in the ileal reservoir after restorative proctocolectomy for ulcerative colitis. A long-term follow-up study. Int J Colorectal Dis. 1998;13:103-7.

160

Setti Carraro PG, Talbot IC, Nicholls JR. Patterns of distribution of endoscopic and histological changes in the ileal reservoir after restorative proctocolectomy for ulcerative colitis. A longterm follow-up study. Int J Colorectal Dis. 1998;13:103-7.

Ferrante M, D'Hoore A, Vermeire S, et al. Corticosteroids but not infliximab increase short-term postoperative infectious com-plications in patients with ulcerative colitis. Inflamm Bowel Dis. 2009;15:1062-70.

161

Lake JP, Firoozmand E, Kang JC, Vassiliu P, et al. Effect of high-dose steroids on anastomotic complications after procto-colectomy with ileal pouch-anal anastomosis. J Gastrointest Surg. 2004;8:547-51.

162

Lake JP, Firoozmand E, Kang JC, Vassiliu P, et al. Effect of high-dose steroids on anastomotic complications after proctocolectomy with ileal pouch-anal anastomosis. J Gastrointest Surg. 2004;8:547-51.

Mahadevan U, Loftus Jr EV, Tremaine WJ, Pemberton JH, Harmsen WS, Schleck CD, et al. Azathioprine or 6-mercaptopu-rine before colectomy for ulcerative colitis is not associated with increased postoperative complications. Inflamm Bowel Dis. 2002;8:311-6.

163

Mahadevan U, Loftus Jr EV, Tremaine WJ, Pemberton JH, Harmsen WS, Schleck CD, et al. Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. Inflamm Bowel Dis. 2002;8:311-6.

Pugliese D, Armuzzi A, Rizzo G, et al. Effect of anti-TNF-alpha treatment on short-term post-operative complications in patients with inflammatory bowel disease. Gut. 2010;59(Suppl III):A13.

164

Pugliese D, Armuzzi A, Rizzo G, et al. Effect of anti-TNF-alpha treatment on short-term post-operative complications in patients with inflammatory bowel disease. Gut. 2010;59(Suppl III):A13.

Subramanian V, Pollok RC, Kang JY, Kumar D. Systematic review of postoperative complications in patients with inflam-matory bowel disease treated with immunomodulators. Br J Surg. 2006;93:793-9.

165

Subramanian V, Pollok RC, Kang JY, Kumar D. Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators. Br J Surg. 2006;93:793-9.

Yang Z, Wu Q, Wang F, Wu K, Fan D. Meta-analysis: effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery. Aliment Pharmacol Ther. 2012 Nov;36(10):922-8. doi: 10.1111/apt.12060. Epub 2012 Sep 24.

166

Meagher AP, Farouk R, Dozois RR, Kelly KA, et al. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and longterm outcome in 1310 patients. Br J Surg. 1998;85:800-3.

167

Meagher AP, Farouk R, Dozois RR, Kelly KA, et al. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg. 1998;85:800-3.

Simchuk EJ, Thirlby RC. Risk factors and true incidence of pouchitis in patients after ileal pouch-anal anastomoses. World J Surg. 2000;24:851-6.

168

Simchuk EJ, Thirlby RC. Risk factors and true incidence of pouchitis in patients after ileal pouch-anal anastomoses. World J Surg. 2000;24:851-6.

Stahlberg D, Gullberg K, Liljeqvist L, Hellers G, et al. Pouchitis following pelvic pouch operation for ulcerative colitis. Incidence, cumulative risk, and risk factors. Dis Colon Rectum. 1996;39:1012-8.

169

Penna C, Tiret E, Kartheuser A, Hannoun L, et al. Function of ileal J pouch-anal anastomosis in patients with familial adenoma-tous polyposis. Br J Surg. 1993;80:765-7.

170

Penna C, Tiret E, Kartheuser A, Hannoun L, et al. Function of ileal J pouch-anal anastomosis in patients with familial adenomatous polyposis. Br J Surg. 1993;80:765-7.

Tjandra JJ, Fazio VW, Church JM, Oakley JR, et al. Similar func-tional results after restorative proctocolectomy in patients with familial adenomatous polyposis and mucosal ulcerative colitis. Am J Surg. 1993;165:322-5.

171

Tjandra JJ, Fazio VW, Church JM, Oakley JR, et al. Similar functional results after restorative proctocolectomy in patients with familial adenomatous polyposis and mucosal ulcerative colitis. Am J Surg. 1993;165:322-5.

Shen B, Lashner BA. Diagnosis and Treatment of Pouchitis. Gastroenterology & Hepatology. 2008;4(5):355-361.

172

Shen B, Lashner BA. Diagnosis and Treatment of Pouchitis. Gastroenterology & Hepatology. 2008;4(5):355-361.

Shen B, Achkar JP, Lashner BA. Irritable pouch syndrome: a new category of diagnosis for symptomatic patients with ileal pouch-anal anastomosis. Am J Gastroenterol. 2002 Apr;97(4):972-7.

173

Shen B, Achkar JP, Lashner BA. Irritable pouch syn-drome: a new category of diagnosis for symptomatic patients with ileal pouch-anal anastomosis. Am J Gastroenterol. 2002 Apr;97(4):972-7.

Korneeva O.I., Ivashkin V.T. Cl.Difficile colitis: pathomorfol-ogy, symptoms and treatment. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2007; 17(3):65-71 (In Russ.)

174

Корнеева О. Н., Ивашкин В. Т. Антибиотикоассоциированный колит: патоморфология, клиника, лечение. Российский журнал гастроэнтерологии гепатологии и колопроктологии. 2007; №17(3), c. 65-70.

Aguado JM, Anttila VJ, Galperine T, Goldenberg SD et al. Highlighting clinical needs in Clostridium difficile infection: the views of European healthcare professionals at the front line. J Hosp Infect. 2015; 2(50): 117-125.

175

Metan G, Türe Z, Kaynar L. Tigecycline for the treatment of Clostridium difficile infection refractory to metronidazole in haematopoietic stem cell transplant recipients. Journal of Chemotherapy. 2015;6(27): 354-357.

176

Chiu CY, Sarwal A, Feinstein A, Hennessey K. Effective Dosage of Oral Vancomycin in Treatment for Initial Episode of Clostridioides difficile Infection: A Systematic Review and Meta-Analysis. Antibiotics (Basel). 2019 Oct 1;8(4). pii: E173. doi: 10.3390/antibiotics8040173.

177

Tschudin-Sutter S, Braissant O, Erb S, et al. Growth Patterns of Clostridium difficile – Correlations with Strains, Binary Toxin and Disease Severity: A Prospective Cohort Study. PLoS One. 2016; 9(11): e0161711.

178

Fomenko O.Yu., Achkasov S.I., Titov A.Yu., Aleshin D.V., et al. Improvement of anal sphincter function before preventive stoma closure: modern options. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015; 5:77-83. (In Russ.).

179

Фоменко О.Ю., Ачкасов С.И., Титов А.Ю., Алешин Д.В., и соавт. Современные возможности улучшения функционального состояния запирательного аппарата у пациентов с наличием превентивных кишечных стом. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015; № 5, с. 77-83.

Fomenko O.Yu., Achkasov S.I., Titov A.Yu., Dzhanaev Yu.A., et al. Role of anorectal manometry, biofeedback therapy and tibial neurostimulation in conservative treatment of anal incontinence in elderly. Clinical gerontology. 2015;5(6):16-20. (In Russ.).

180

Фоменко О.Ю., Ачкасов С.И., Титов А.Ю., Джанаев Ю.А., и соавт. Роль аноректальной манометрии, БОС-терапии и тибиальной нейромодуляции в диагностике и консервативном лечении анальной инконтиненции у пожилых. Клиническая геронтология. 2015; № 5-6, с. 16-20.

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States. Am J Respir Crit Care Med. 2005. 172(9): 1169-227.

181

The authors declare that there are no conflicts of interest present.